구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | E7 TCR-T cells (E7 TCR-T cells) Iovance Biotherapeutics, Inc.·HPV-Associated Cervical Carcinoma 11 trials |
|---|---|
Overview Program | E7 TCR-T cells |
Overview Company | Iovance Biotherapeutics, Inc. |
Overview Modality | CGT |
Overview Target | HPV-Associated Cervical Carcinoma |
Overview Indication | HPV-Associated Cervical Carcinoma; HPV-Related Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentation.. To leverage complementary mechanisms for cancer cell removal, we developed a novel cell engineering and therapeutic strategy co-opting phagocytic clearance and antigen presentation activity int… |
Toxicology CRS | Reported |
Clinical Safety signal | Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentation.. To leverage complementary mechanisms for cancer cell removal, we developed a novel cell engineering and therapeutic strategy co-opting phagocytic clearance and antigen presentation activity int… |
Clinical Selected reported efficacy | ORR 5% |
Clinical Reported ORR | 5% |
Clinical Result source | ClinicalTrials.gov NCT02858310 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02858310 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | E7 TCR-T cells (E7 TCR-T cells) Iovance Biotherapeutics, Inc.·HPV-Associated Cervical Carcinoma 11 trials |
|---|---|
Overview Program | E7 TCR-T cells |
Overview Company | Iovance Biotherapeutics, Inc. |
Overview Modality | CGT |
Overview Target | HPV-Associated Cervical Carcinoma |
Overview Indication | HPV-Associated Cervical Carcinoma; HPV-Related Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentation.. To leverage complementary mechanisms for cancer cell removal, we developed a novel cell engineering and therapeutic strategy co-opting phagocytic clearance and antigen presentation activity int… |
Toxicology CRS | Reported |
Clinical Safety signal | Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentation.. To leverage complementary mechanisms for cancer cell removal, we developed a novel cell engineering and therapeutic strategy co-opting phagocytic clearance and antigen presentation activity int… |
Clinical Selected reported efficacy | ORR 5% |
Clinical Reported ORR | 5% |
Clinical Result source | ClinicalTrials.gov NCT02858310 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02858310 |
추천 비교
추천 비교